Associated bone mineral density and obstructive sleep apnea in chronic obstructive pulmonary disease

Tsai-Yu Wang¹
Yu-Lun Lo¹,²
Pai-Chien Chou¹
Fu-Tsai Chung¹
Shu-Min Lin¹
Ting-Yu Lin¹
Horng-Chuyan Lin¹
Chun-Hua Wang¹
Chih-Teng Yu¹
Han-Pin Kuo¹

¹Department of Thoracic Medicine, School of Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taipei, Taiwan;
²Healthcare Center, Chang Gung Memorial Hospital, Taipei, Taiwan

Background: Osteoporosis is an important issue for patients with chronic obstructive pulmonary disease (COPD). Worse systemic inflammation and reduced exercise capacity have been reported in COPD patients with obstructive sleep apnea (OSA), implying that OSA may be an independent factor for osteoporosis in COPD patients.

Methods: A total of 66 patients with bone mineral density (BMD) and polysomnography results from a previous COPD cohort (January 2008 to January 2013) were retrospectively enrolled. Clinical characteristics such as medication, pulmonary function, BMD, and results of polysomnography were analyzed.

Results: The BMD in those with OSA was significantly lower than in those without OSA (−1.99±1.63 versus −1.27±1.14, P=0.045). In univariate analysis, body mass index, forced expiratory volume in 1 second, percentage of predicted value, incremental shuttle walk test, apnea–hypopnea index, and oxygen desaturation index (ODI) were significantly associated with BMD. After multivariate linear regression analysis, the ODI was still an independent factor for BMD. In addition, smaller total lung capacity is significantly associated with higher ODI and lower BMD, which implies that lower BMD might cause severer OSA via decreased total lung capacity.

Conclusion: OSA may be an independent factor for BMD in patients with COPD, which implies a possible vicious cycle takes place in these patients.

Keywords: chronic obstructive pulmonary disease, osteoporosis, total lung capacity

Introduction
Chronic obstructive pulmonary disease (COPD) is a serious health burden and a major cause of mortality worldwide. Aside from the progressive loss of pulmonary function, extra-pulmonary comorbidities such as low skeletal muscle mass, cardiovascular disease, pulmonary hypertension, obstructive sleep apnea (OSA), and osteoporosis play an important role in the mortality of COPD patients.

Osteoporosis, characterized by a decrease in bone mineral density (BMD), is reported to affect 9%–69% of patients with COPD, indicating that COPD patients have a high risk of developing osteoporosis. The etiology of osteoporosis in COPD patients is complex and variable, and includes chronic systemic inflammation (TNF-α promoting bone loss), therapy (corticosteroid treatment), and natural changes because of aging, physical deconditioning (low skeletal muscle mass).

With regard to physical activity, a recent study revealed that walking capacity is impaired when COPD patients have OSA, also called the overlap syndrome. In addition, this impairment can be partially reversed by continuous positive airway pressure...
(CPAP) treatment, implying that OSA is a possible cause for the low level of physical activity in COPD patients. Moreover, a low level of physical activity may lead to negative effects in patients with osteoporosis. Furthermore, OSA patients have been reported to have a higher avidity and cytotoxicity of γδ T-cells, which are mainly attributed to the proinflammatory cytokine TNF-α. TNF-α promotes further bone loss, which may further contribute to osteoporosis. Therefore, OSA may be a possible etiology responsible for osteoporosis in COPD patients, a finding that has not previously been reported. The primary aim of this study was to evaluate the BMD between COPD patients with and without OSA. The secondary aim was to evaluate the association between BMD and severity of OSA.

Materials and methods

Study population

We retrospectively recruited patients with COPD from January 2008 to January 2013 in Chang Gung Memorial Hospital, a tertiary hospital in Taiwan. Patients were excluded if data of BMD and polysomnography were not available or if the patients had any history of malignancy. Those COPD patients would be referred to sleep laboratory while they had snoring. Therefore, data of polysomnography were not available if those COPD patients had no snoring history. The Chang Gung Medical Foundation Institutional Review Board approved this study (102-3093B) and waived the requirement for informed consent due to the retrospective nature of the study.

Study design

The medical records of each patient were reviewed to collect the clinical characteristics and laboratory results. In addition, data on BMD, polysomnography, pulmonary function, incremental shuttle walk test (ISWT), and medications were analyzed.

Definitions

COPD was defined as forced expiratory volume in 1 second/forced vital capacity (FEV₁/FVC) ratio less than 70% and an increase in forced expiratory volume in 1 second less than 12% of baseline after inhalation of β₂ agonist. Based on the polysomnography results, OSA was defined as an apnea–hypopnea index (AHI) >15 per hour, of which ≥50% were obstructive. Sleep stages and arousals were scored according to the AASM criteria. Established criteria were used to score respiratory events such as hypopnea, obstructive apnea, central apnea, mixed-type apnea, and Cheyne–Stokes respiration. Apnea was defined as oronasal flow cessation for more than 10 seconds. Hypopnea was defined as a 50% reduction in oronasal flow for more than 10 seconds; or a 30% reduction followed, by arousal or more than 3% decrease in oxygen saturation. The BMD was determined by dual-energy X-ray absorptiometry. The BMD was expressed as a T-score (standard deviations from a young, sex-specific reference mean BMD). ISWT was performed as in a previous study.

Statistical analysis

Data were expressed as mean ± standard deviation or mean ± standard error of the mean. The Student’s t-test was used for comparisons of continuous variables between those with and without OSA, while the Mann–Whitney test was used for non-normal distributions. Categorical variables were compared by chi-square or Fisher’s exact tests. The Pearson product correlation coefficient was used to examine correlations between variables and the BMD. Multivariate linear regression analysis was used to determine the independent factors associated with the BMD. A P-value less than 0.05 was considered to be statistically significant. All analyses were performed using the SPSS software package version 13.0 (SPSS Inc., Chicago, IL, USA).

Results

Demographic and clinical characteristics of the patients

A total of 312 patients with COPD were identified between January 2008 and January 2013, 30 of whom were excluded due to the following reasons: 194 (62.2%) did not have polysomnography data; 45 (14.4%) had malignancy; and seven (2.2%) did not have data on dual-energy X-ray absorptiometry for BMD. The records of the remaining 66 patients were further reviewed, of whom 35 had OSA and 31 did not. The baseline demographic data and clinical characteristics of these patients are listed in Table 1. The mean ages of the COPD patients with and without OSA were similar (71.5 and 71.6 years, respectively). The BMD in those with OSA was significantly lower than that in those without OSA (−1.99 ± 1.63 versus −1.27 ± 1.14, P=0.045). Other characteristics including smoking, pulmonary function, and medications (including inhaled corticosteroids, long-acting β₂ agonists, long-acting muscarinic antagonists,
theophylline, oral corticosteroids, and proton pump inhibitors) were similar between the two groups. With regards to the polysomnographic results (Table 2), the mean AHI in those with OSA was 37.0±16.7/h of sleep, indicating that most of the patients had severe OSA, accompanied by greater desaturation (lowest oxygen saturation 80.7%) and less rapid eye movement stage (8% of total sleep time).

### Univariate and multivariate linear regression analysis for the variables associated with BMD

In univariate analysis, body mass index (BMI), FEV$_1$, %, ISWT, AHI, and oxygen desaturation index (ODI) (Figure 1) were significantly correlated with BMD at the lumbar spine (Table 3), while age and use of inhaled corticosteroids, oral corticosteroids, and proton pump inhibitors were not. The multivariate stepwise linear regression analysis was used to analyze the independent factors contributing to BMD (Table 4). The association between BMD and AHI is revealed in Figure 1. Although, BMI, FEV$_1$, %, ISWT, AHI, and ODI were chosen to be analyzed in multivariate stepwise linear regression, only BMI, FEV$_1$, %, and ODI were independent factors for BMD.

### The association between total lung capacity, BMD, and ODI

Figure 2 reveals an association between total lung capacity and ODI ($P<0.01$, $R=0.327$, $N=66$). In addition, an association between total lung capacity and BMD is shown in Figure 3. ($P=0.025$, $R=0.314$, $N=66$)

### Discussion

The results of this study demonstrated that the BMD was worse in those with OSA than in those without OSA. In multivariate analysis, ODI was still significantly associated

---

### Table 1 Patients characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>COPD without OSA (n=31)</th>
<th>COPD with OSA (n=35)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>71.6±8.5</td>
<td>71.5±8.6</td>
<td>0.951</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>29 (93.5)</td>
<td>33 (94.3)</td>
<td>0.348</td>
</tr>
<tr>
<td>BMI</td>
<td>23.8±3.4</td>
<td>24.9±4.3</td>
<td>0.958</td>
</tr>
<tr>
<td>Smoke, PKY</td>
<td>50.5±28.9</td>
<td>51.7±22.3</td>
<td>0.850</td>
</tr>
<tr>
<td>Pulmonary function test</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV/FVC</td>
<td>55.5±9.4</td>
<td>54.4±10.4</td>
<td>0.651</td>
</tr>
<tr>
<td>FEV, (% predicted)</td>
<td>46.8±15.9</td>
<td>46.4±23.0</td>
<td>0.927</td>
</tr>
<tr>
<td>FVC, (% predicted)</td>
<td>60.2±15.7</td>
<td>61.1±23.9</td>
<td>0.850</td>
</tr>
<tr>
<td>Incremental shuttle</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>walk test, m</td>
<td>279.7±107.2</td>
<td>240.9±88.4</td>
<td>0.168</td>
</tr>
<tr>
<td>BMD</td>
<td>T-score (lumbar spine L2–4)</td>
<td>-1.27±1.14</td>
<td>-1.99±1.63</td>
</tr>
<tr>
<td>Medication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LABA, n (%)</td>
<td>29 (93.5)</td>
<td>32 (91.4)</td>
<td>0.999</td>
</tr>
<tr>
<td>ICS, n (%)</td>
<td>29 (93.5)</td>
<td>32 (91.4)</td>
<td>0.999</td>
</tr>
<tr>
<td>LAMA, n (%)</td>
<td>24 (77.4)</td>
<td>31 (88.6)</td>
<td>0.324</td>
</tr>
<tr>
<td>Theophyllines, n (%)</td>
<td>7 (22.6)</td>
<td>12 (34.3)</td>
<td>0.415</td>
</tr>
<tr>
<td>Oral</td>
<td>11 (35.5)</td>
<td>7 (20)</td>
<td>0.178</td>
</tr>
<tr>
<td>corticosteroids, n (%)</td>
<td>11 (35.5)</td>
<td>17 (48.6)</td>
<td>0.326</td>
</tr>
</tbody>
</table>

Note: Data are presented as mean ± standard deviation, or number (percentage).

Abbreviations: BMD, bone mineral density; BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, Inhaled corticosteroids; LABA, long-acting B$_2$ agonist; LAMA, long-acting muscarinic antagonist; OSA, obstructive sleep apnea; PKY, pack years; PPI, proton pump inhibitor.

---

### Table 2 Polysomnographic results

<table>
<thead>
<tr>
<th></th>
<th>COPD without OSA (n=31)</th>
<th>COPD with OSA (n=35)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total sleep time (minutes)</td>
<td>277.4±71.8</td>
<td>254.8±70.5</td>
<td>0.206</td>
</tr>
<tr>
<td>Sleep efficiency (%)</td>
<td>67.8±13.5</td>
<td>64.2±14.9</td>
<td>0.316</td>
</tr>
<tr>
<td>AHI events per hour</td>
<td>8.6±3.9</td>
<td>37.0±16.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ODI events per hour</td>
<td>4.4±3.6</td>
<td>21.1±15.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Average SaO$_2$, %</td>
<td>93.7±2.2</td>
<td>93.2±2.5</td>
<td>0.363</td>
</tr>
<tr>
<td>Lowest SaO$_2$, %</td>
<td>87.6±4.2</td>
<td>80.7±8.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Wake % TST</td>
<td>25.6±13.7</td>
<td>28.5±13.4</td>
<td>0.407</td>
</tr>
<tr>
<td>N1 % TST</td>
<td>18.8±12.1</td>
<td>20.5±19.9</td>
<td>0.525</td>
</tr>
<tr>
<td>N2 % TST</td>
<td>32.9±14.0</td>
<td>36.5±12.1</td>
<td>0.273</td>
</tr>
<tr>
<td>N3 % TST</td>
<td>10.8±11.0</td>
<td>6.5±9.1</td>
<td>0.091</td>
</tr>
<tr>
<td>REM % TST</td>
<td>11.7±6.8</td>
<td>8.0±7.1</td>
<td>0.032</td>
</tr>
</tbody>
</table>

Note: Data are presented as mean ± standard deviation.

Abbreviations: AHI, apnea–hypopnea index; COPD, chronic obstructive pulmonary disease; OSA, oxygen desaturation index; OSA, obstructive sleep apnea; REM, rapid eye movement; SaO$_2$, oxygen saturation; TST, total sleep time.

---

Figure 1 Correlation analysis: an association between bone mineral density and apnea–hypopnea index.
with BMD, which suggested that OSA played an important role in lower BMD in COPD patients. To the best of our knowledge, this finding has not previously been reported.

Osteoporosis is one of the systemic effects of COPD. Moreover, osteoporosis is associated with the COPD mortality. However, the detailed mechanism by which osteoporosis develops in COPD patients is still under debate. It is likely that the pathogenesis is multifactorial and includes age, progressive reduction of physical activity, low BMI, disease severity (FEV1), systemic use of corticosteroids, and systemic inflammation. Age was not associated with BMD in this study, which may be due to the small age span of the study population. The BMI and FEV1 were significantly associated with osteoporosis, which was compatible with previous reports. Interestingly, ODI as a cardinal feature of OSA was also an independent contributing factor to BMD, which may be explained by two possible reasons. One is the systemic inflammation and another one is reduced physical activity, which may be explained by repetitive upper airway collapse and intermittent hypoxemia, and then it may affect the activity of osteoblasts and osteoclasts. Another possible reason is the reduced level of physical activity in COPD patients with OSA.

With regards to systemic inflammation, increased concentrations of circulating inflammatory mediators such as TNF-α, IL-1, and IL-6 have been reported in COPD patients. Moreover, oxidative stresses are associated with bone resorption during COPD exacerbation. TNF-α stimulates osteoblastic cells to express RANKL and M-CSF, which in turn prompt macrophages to become osteoclasts, leading to bone resorption. In addition, TNF-α and IL-1, via activation of osteoclast surface receptors, potentiate osteoclastogenesis and bone resorption. In addition, IL-6 is known to stimulate the formation of osteoclasts. OSA is accompanied by oxidative stress and inflammation via activation of NF-kB and downstream pathway. Moreover, some evidence also revealed that...
TNF-α, IL-1, and IL-6 are significantly elevated in patients with OSA,30,31,32 In addition, hypoxia also induces the formation of giant osteoclasts.33 Therefore, it is reasonable that the existence of OSA will lead to worsened BMD in COPD patients.

Physical activity is an important factor associated with osteoporosis. It has been reported to contribute to increased peak bone mass in youths,34,35 maintain bone mass in premenopausal women, and decrease loss of bone mass in postmenopausal women.36 The benefits of physical activity in the prevention of osteoporosis have been revealed.37,38 Interestingly, a pronounced reduction in exercise capacity in COPD patients was observed in a previous study. In COPD patients who have OSA, the exercise capacity will be worse, although this can be restored with CPAP treatment.39 Therefore, this reduced level of physical activity may be another possible reason for the worse BMD in COPD patients with OSA.

Increases in lung volume have been documented to dilate the pharynx and decrease its collapsibility, which suggests that increases in lung volume will ameliorate the severity of OSA.39-41 In addition, the lower BMD is associated with lower total lung capacity in the present study. Similarly, a recent study revealed that COPD patients with osteoporosis are associated with deteriorated pulmonary function.42 In addition, while COPD patients with osteoporosis received vertebroplasty for the osteoporotic vertebral compression fractures, the pulmonary function can be improved after this procedure.43 Decreases in lung volume in COPD patients with osteoporosis will deteriorate the severity of OSA. In addition, OSA will further deteriorate the osteoporosis in COPD patients. Therefore, while COPD patients have OSA, they will be in vicious cycle.

The major limitations of the present study are its retrospective nature, which may have led to bias in patient selection. Second, the sample size of the study is modest, and therefore the results of the study should be interpreted with caution. A prospective study with a larger sample size is warranted to further confirm the results. Physical activity has been reported as an independent factor associated with osteoporosis. However, ISWT was not an independent factor under multivariate analyses. The possible reason may be that ISWT is considered a measurement of maximal exercise capacity, not a measurement of daily activity.44 Therefore, the 6-minute walk test may be used to confirm if daily physical activity is an independent factor for osteoporosis in COPD patients with OSA in the further study. Finally, the population in this study was based in a sleep lab, so extrapolation of the results to the general population should be done with caution.

Conclusion

In conclusion, the BMD of COPD patients with OSA was significantly worse than that of COPD patients without OSA. Moreover, ODI was still an independent factor associated with BMD in multivariate analysis. In addition, smaller total lung capacity is significantly associated with higher ODI and lower BMD, which implies that lower BMD might cause severer OSA via decreased total lung capacity. Therefore, OSA may be a contributory factor to BMD in patients with COPD.

Acknowledgments

The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript. This study was supported by a research grant from the Chang Gung Memorial Hospital (CMRPG3D0471). Dr Tsai-Yu Wang contributed to conceptualization and design of this study; collection, analysis, and interpretation of the data; and preparation of the manuscript. Dr Yu-Lun Lo contributed to conceptualization and design of this study, collection, analysis, interpretation of the data and preparation of the manuscript. Pai-Chien Chou, Fu-Tsai Chung, Shu-Min Lin, Ting-Yu Lin, Horng-Chyuan Lin, Chun-Hua Wang, and Chih-Teng Yu contributed to collection, analysis, and interpretation of the data and preparation of the manuscript. Dr Han-Pin Kuo contributed to conceptualization and design of the study; collection and interpretation of the data; and preparation of the manuscript.

Disclosure

The authors report no conflicts of interest in this work.

References


